Medical Program: Assessing Biosimilar Medications for Inflammatory Bowel Diseases

Assessing Biosimilar Medications for Inflammatory Bowel Diseases

ReachMD Healthcare Image
RestartResume

What do we need to know about biosimilars before applying them to IBD patient care? Two experts from the FDA weigh in.

  • Overview

    Biosimilar medications have now entered the clinical landscape of treatment protocols for several disciplines—including gastroenterology. Joining Dr. Thomas Ullman to discuss the biosimilars that are available for Crohn’s disease and ulcerative colitis and how other parts of the world are using them are Dr. Sarah Yim, Acting Director of the Office of Therapeutic Biologics & Biosimilars, and Dr. Juli Tomaino, a pediatric gastroenterologist and Lead Medical Officer at the FDA.

  • Publish Date

    Release Date: 11/06/2019

Facebook Comments

Register

We’re glad to see you’re enjoying Crohn's Colitis Professional…
but how about a more personalized experience?

Register for free